Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Infusion of Methylene Blue in Severe Sepsis and Septic Shock
NCT01797978Phase 3Unknown
- Sponsor
- Seoul National University Hospital
- Start
- Feb 2013
- Primary completion
- Jan 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, single-blind trial in sepsis and septic shock comparing Intravenous methylene blue administration with Placebo (2 arms). Primary endpoint: 28 day mortality. Status: unknown.
02
Drugs
methylene blue
03
Conditions
sepsisseptic shock
Beyond the preview
Go deeper on NCT01797978.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01797978.